Completed OBSERVATIONAL NCT04833504

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma Primary Mediastinal Large B-cell Lymphoma Transformed Follicular Lymphoma

Interventions CD19 CAR-T Expressing IL7 and CCL19

Updated 4 times since 2021 Last updated: Jul 13, 2025 Started: Sep 22, 2018 Primary completion: Sep 22, 2023 Completion: Oct 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma and is currently completed. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 4 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Completed
Sep 2024 — Aug 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2021 — Jul 2024 [monthly]

Completed

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China